Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid
The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are based on inflammatory processes. The novel multicomponent crystals contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid (diclofenac) as the sole active ingredient combination and can be produced by dissolving the two components in a molar ratio of 1.0:0.9 to 1.0:1.1 in an inert organic solvent and subsequently crystallizing the complex compound.
1. Multicomponent crystal, characterized in that it consists of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl] carbamic acid ethyl ester (flupirtine) and 2-[2-[(2,6-dichlorophenyl)-amino]-phenyl] acetic acid (diclofenac), wherein the molar ratio of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl] carbamic acid ethyl ester and 2-[2-[(2,6-dichlorophenyl)-amino]-phenyl] acetic acid is in the range of 0.9 : 1 to 1.1 : 1.0, further characterized by an X-ray powder diffractogram with a characteristic peak at 2θ=6.1±0.2° and additionally characterized by an X-ray powder diffractogram with a characteristic peak at 2θ=4.9±0.2°, 7.7 ±0.2°, and 19.6±0.2°.
2. Multicomponent crystal according to claim 1 , additionally characterized by an X-ray powder diffractogram with a characteristic peak at 2θ=11.1±0.2°, 12.3±0.2°, 14.6±0.2°, 20.9±0.2°, 22.5±0.2°, 24.2±0.2° and 24.8±0.2°.
3. Multicomponent crystal according to claim 1 , characterized by a DSC thermogram with a melting endothermal peak in the range of 100 to 115° C. with an onset temperature of 96.9±2° C. and with a peak maximum at 107.2° C.±3° C.
4. Method for producing a multicomponent crystal according to claim 1 , comprising the steps:
a) dissolving of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl] carbamic acid ethyl ester and 2-[2-[(2,6-dichlorophenyl)-amino]-phenyl] acetic acid in a molar ratio of 1.0 : 0.9 to 1.0 : 1.1 in an inert organic solvent and
b) crystallizing the complex compound.
5. Pharmaceutical preparation comprising a multicomponent crystal according to claim 1 as an active ingredient combination.
6. Pharmaceutical preparation according to claim 5 in the form of a soft capsule.
7. Transdermal pharmaceutical preparation comprising a multicomponent crystal according to claim 1 as an active ingredient.
8. Oral pharmaceutical preparation according to claim 5 , wherein the pharmaceutical preparation contains 50 to 1,000 mg per administration unit of said multicomponent crystal.
9. A method of treating a patient suffering from acute and chronic pains, selected from the group consisting of neuropathic pain, nerve pain, pain caused by cancer diseases, tension headaches, vasomotoric and migraine headaches, pain conditions after operations, after injuries, burns, chemical burns, dysmenorrhea pain, toothache, arthritic pain, and inflammation pain, the method comprising administering to said patient an effective amount of the multicomponent crystal of claim 1 .
10. The method according to claim 9 for treating muscle tension, muscle spasm, muscle stiffness, and back pain.
11. The method according to claim 9 , comprising simultaneously treating pain of different causes.
12. Method for producing a pharmaceutical preparation comprising mixing of a complex compound according to claim 1 with a glycol-containing solvent, a solutizer, and a viscosity-imparting agent, and introducing the mixture into a soft gelatine capsule.
13. Transdermal pharmaceutical preparation according to claim 7 , wherein the pharmaceutical preparation contains 50 to 1,000 mg per administration unit of said multicomponent crystal.
14. A method of treating a patient suffering from acute and chronic pains, selected from the group consisting of neuropathic pain, nerve pain, pain caused by cancer diseases, tension headaches, vasomotoric and migraine headaches, pain conditions after operations, after injuries, burns, chemical burns, dysmenorrhea pain, toothache, arthritic pain, and inflammation pain, the method comprising administering to said patient an oral pharmaceutical preparation, comprising a multicomponent crystal according to claim 1 as an active ingredient combination, in an effective amount.
15. A method of treating a patient suffering from acute and chronic pains, selected from the group consisting of neuropathic pain, nerve pain, pain caused by cancer diseases, tension headaches, vasomotoric and migraine headaches, pain conditions after operations, after injuries, burns, chemical burns, dysmenorrhea pain, toothache, arthritic pain, and inflammation pain, the method comprising administering to said patient a transdermal pharmaceutical preparation, comprising a multicomponent crystal according to claim 1 as an active ingredient combination, in an effective amount.
16. A method of treating a patient suffering from muscle tension, muscle spasm, muscle stiffness, and back pain, the method comprising administering to said patient an oral pharmaceutical preparation, comprising a multicomponent crystal according to claim 1 as an active ingredient combination, in an effective amount.
17. A method of treating a patient suffering from muscle tension, muscle spasm, muscle stiffness, and back pain, the method comprising administering to said patient a transdermal pharmaceutical preparation, comprising a multicomponent crystal according to claim 1 as an active ingredient combination, in an effective amount.
18. A method of treating a patient suffering from pain of different causes, the method comprising administering to said patient a pharmaceutical preparation, comprising a multicomponent crystal according to claim 1 as an active ingredient combination, in an effective amount, wherein the pharmaceutical preparation is selected from the group consisting of an oral preparation and a transdermal preparation.
19. The method according to claim 18 , wherein the pain of different causes comprises inflammatory pain and pain caused by muscle tension.
20. The method according to claim 11 , wherein the pain of different causes comprises inflammatory pain and pain caused by muscle tension.